Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.14M | 1.98M | 2.45M | 2.71M | 3.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23M | 2.22M | 3.12M | 3.53M | 4.30M |
| Operating Income | -3.23M | -2.22M | -3.12M | -3.53M | -4.30M |
| Income Before Tax | -5.21M | -7.49M | -1.90M | -3.71M | -3.77M |
| Income Tax Expenses | 85.00K | -1.09M | -- | -- | -- |
| Earnings from Continuing Operations | -5.30M | -6.40M | -1.90M | -3.71M | -3.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.30M | -6.40M | -1.90M | -3.71M | -3.77M |
| EBIT | -3.23M | -2.22M | -3.12M | -3.53M | -4.30M |
| EBITDA | -3.22M | -2.22M | -3.12M | -3.52M | -4.29M |
| EPS Basic | -392.42K | -627.01K | -192.68K | -434.38K | -621.93K |
| Normalized Basic EPS | -1.75 | -1.03 | -2.45 | -3.44 | -3.59 |
| EPS Diluted | -392.42K | -627.01K | -192.68K | -434.38K | -621.93K |
| Normalized Diluted EPS | -1.75 | -1.03 | -2.45 | -3.44 | -3.59 |
| Average Basic Shares Outstanding | 1.08M | 816.60K | 786.80K | 682.40K | 485.20K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |